VDR Genotype

Two people can take the same vitamin D dose, hit the same blood level, and get different results in their bones, immune system, and metabolism. Some of that gap may trace back to the gene that codes for the protein your cells use to act on vitamin D. Knowing your version of this gene is a one-time piece of information that can add context to how you interpret your vitamin D labs and your family disease risks, though the effect sizes reported in the literature are generally modest.

This test reports your VDR (vitamin D receptor) genotype at one or more common variant positions. The result does not change over your lifetime, and it does not replace measuring your vitamin D level. Before going further, an honest disclosure: no major medical society, including the Endocrine Society in its 2024 vitamin D guideline, currently recommends VDR genotype testing for any clinical purpose. The associations described below are real findings from published research, but they have not been shown to improve outcomes when used to guide medical decisions.

What VDR Actually Does in Your Body

VDR is a protein found in almost every tissue, including gut lining, immune cells, bone, muscle, brain, liver, and skin. When active vitamin D binds to VDR, the receptor switches on or off many genes that control calcium absorption, immune balance, the tight seal between gut cells, and the way bone is built and broken down.

Common inherited variants in the VDR gene (such as FokI, BsmI, ApaI, and TaqI) have been studied as risk modifiers across many conditions. The size of the effect is usually modest (odds ratios commonly in the 1.1 to 1.5 range), and the picture varies by ancestry. BsmI, ApaI, and TaqI also sit close together on the gene and are inherited as a block in many populations, so they are not fully independent signals. Treat this result as one piece of information that nudges probabilities, not a verdict.

Heart and Cardiometabolic Risk

A large analysis of nearly 400,000 adults found that VDR polymorphisms modify the relationship between vitamin D status and cardiometabolic multimorbidity, meaning the same vitamin D level can carry different risk depending on your VDR variant. A separate trial sequential analysis of four common VDR polymorphisms reported that one variant (rs1544410) was linked to higher coronary artery disease risk, while another (rs7975232) appeared protective.

A meta-analysis of essential hypertension found the BsmI VDR variant was tied to lower hypertension risk, with ApaI and TaqI showing no significant link. Smaller studies in specific populations (such as a Bangladeshi cohort) linked the FokI variant to higher hypertension susceptibility. The pattern across studies is real but not consistent enough to use a single VDR variant to predict your own cardiovascular trajectory.

Type 2 Diabetes and Microvascular Complications

In a prospective study of 14,709 people with type 2 diabetes, higher vitamin D levels were tied to lower risk of diabetic eye, kidney, and nerve complications, and VDR polymorphisms shifted the strength of that protection. A separate large cohort reported a similar pattern for type 2 diabetes risk itself: vitamin D status appeared to matter more or less depending on VDR variant.

An important caveat: a rigorous meta-analysis that applied false-positive report probability and Bayesian false discovery testing concluded that the significant VDR associations with type 2 diabetes were likely less credible positive results rather than true associations. In other words, the published links between VDR variants and diabetes may not hold up under stricter statistical scrutiny.

Inflammatory Bowel Disease and Crohn's

VDR is heavily expressed in the gut lining, where it helps maintain the tight seal between intestinal cells and keeps inflammation in check. A small observational study of 176 people with Crohn's disease found that the ApaI variant was associated with disease phenotype, progression, and treatment response, with the aa genotype tied to less severe outcomes.

A separate small study of 103 Crohn's patients linked a specific VDR variant to lower VDR protein in immune cells, higher inflammation, and a higher rate of penetrating (fistula-forming) disease and surgery. Both studies are small and hypothesis-generating, and the findings have not been replicated in large multi-center cohorts. If you have a family history of inflammatory bowel disease, VDR genotype is one of many inherited factors that may be worth knowing about.

Cancer Risk and Prognosis

A meta-analysis covering many cancer sites found that VDR FokI and BsmI variants modestly modulate the risk of breast, skin, and prostate cancers, with effects varying by ancestry. A meta-analysis of 39 breast cancer studies pointed to the FokI variant as the most consistent risk modifier. In an umbrella review of melanoma, the FokI variant was tied to higher risk while BsmI looked protective, though the authors flagged that more data are needed.

For colorectal cancer, a systematic meta-analysis linked the BsmI variant to higher colon cancer risk (but not rectal). A study of 537 people found that homozygous mutant VDR genotypes were associated with worse overall survival. These are population-level signals with modest effect sizes; no guideline currently uses VDR genotype to tailor cancer screening or treatment.

Bone Health and Osteoporosis

VDR is central to calcium absorption and bone remodeling, which made it a logical candidate for explaining inherited differences in bone density. Smaller studies have reported associations: a study of 602 Belarusian postmenopausal women found that specific VDR genetic markers correlated with osteoporosis risk and bone mineral density, and a preliminary study of 79 patients with systemic sclerosis tied the FokI variant to lower spine bone mineral density.

The strongest evidence here, however, points the other way. The GENOMOS consortium pooled participant-level data from 26,242 people and found that the FokI, BsmI, ApaI, and TaqI VDR polymorphisms were not associated with bone mineral density or fractures, with any genotype difference smaller than 0.011 g/cm². An updated meta-analysis reached a similar conclusion: positive VDR-osteoporosis associations are likely false-positive results. Honest reading of the totality of evidence: VDR variants are not a reliable predictor of bone density or fracture risk.

Parkinson's Disease and Neurological Risk

VDR is present in many brain regions, including the substantia nigra (the area damaged in Parkinson's). A small study of 392 people found that specific VDR variants were tied to Parkinson's susceptibility and to certain side effects from dopamine-based treatment. A separate case-control study of 200 people in Bangladesh linked the ApaI and FokI variants to higher Parkinson's risk. These are small, hypothesis-generating studies, and the clinical actionability of the findings remains unproven. Reviews of underlying biology suggest VDR insufficiency may raise risk for both Alzheimer's and Parkinson's disease, but this is a research signal, not a basis for individual prediction.

Liver Disease

In a study of 229 people with biopsy-proven nonalcoholic fatty liver disease, the rs1544410 CC genotype (BsmI) and low vitamin D were independently tied to more advanced liver fibrosis. A study of 104 people with chronic liver disease found that specific VDR variants influenced VDR protein levels and function. These are interesting research findings, not a clinical basis for ordering liver imaging or fibrosis testing on the strength of genotype alone. Decisions about evaluating fatty liver should be guided by standard risk factors and clinical assessment, not by VDR genotype.

Response to Vitamin D Supplementation

A systematic review and meta-analysis of vitamin D supplementation trials found that people with the TaqI and FokI variants had a somewhat stronger 25-hydroxyvitamin D response to the same dose of vitamin D. In a randomized controlled trial of 90 monozygotic twins, 2,000 IU per day of vitamin D for two months raised serum vitamin D and VDR gene expression.

Keep the contribution in perspective. The largest determinants of how your blood level responds to a vitamin D dose are dose itself and your starting level. Across vitamin D pathway genes, variants in CYP2R1 and the vitamin D binding protein gene (GC/DBP) appear to be stronger genetic predictors of supplementation response than VDR variants, and in at least one major randomized trial analysis only CYP2R1 remained significant after correction for multiple testing. VDR genotype contributes something here, but it is one piece of a larger picture.

Reconciling Mixed Findings

If you scan the literature, you will find studies that link a given VDR variant to higher risk for one disease and lower risk for another, or no association at all. Part of this is genuine biology: VDR is a master regulator that touches dozens of pathways, and its variants tilt different pathways in different directions depending on tissue, ancestry, and vitamin D status. Part of it is also a statistical reality. Effect sizes are small, populations differ, and many positive findings do not survive when tested in larger or more rigorous cohorts. Treat your VDR result as a research-grade phenotype indicator that adds context, not a single up-or-down risk score.

One-Time Result, Lifetime of Decisions

VDR genotype is fixed. You inherited it from your parents, and it will be the same if you test again next year or in thirty years. There is no reason to repeat this test unless a confirmatory method is needed to verify an unexpected call. The value, such as it is, comes from holding the result alongside your standard care: how to interpret a vitamin D level, how to think about a family history of an associated condition, and how to interpret your response to vitamin D supplementation. The Endocrine Society does not recommend routine 25-hydroxyvitamin D screening in healthy adults, and no guideline supports genotype-guided changes to screening intervals.

If your physician already monitors your vitamin D level, your VDR result can give them one extra data point. If you and your physician decide that more frequent companion testing (such as a bone density scan in someone with strong osteoporosis risk factors) makes sense, that decision should rest on the full clinical picture, not on VDR genotype alone.

When Results Can Be Misleading

• Variant panel coverage: the test only detects the specific variants it is designed to read. A negative result does not rule out rare or unstudied variants elsewhere in the VDR gene that could still influence your biology.
• Ancestry differences: the clinical meaning of a variant depends on the population it was studied in. A variant that raises risk in European cohorts may have a different effect in East Asian or African populations, and most published research is European-skewed.
• Linkage disequilibrium: BsmI, ApaI, and TaqI are inherited together in many populations, so their reported associations are not fully independent signals.
• Variants of uncertain significance: some VDR positions can return a call with unclear clinical meaning. Do not assume an unfamiliar variant is benign or dangerous without specialist input.
• Direct-to-consumer mismatches: consumer genetic reports may use different variant calls or coverage than a clinical-grade panel, so do not assume an old 23andMe-style result matches what this test reports.

What to Do With an Unexpected Result

If you carry a variant linked to elevated risk for a specific condition, the next step is not to retest the gene. The next step is to bring the result to your physician and integrate it into a fuller clinical picture: vitamin D level, relevant family history, and any standard risk factors for the condition in question. No current guideline supports automatically tightening screening intervals or supplementation targets based on VDR genotype alone, so any such decision should be made jointly with your clinician based on the full set of factors.

Talk to your biological relatives if a notable finding feels worth sharing. Your siblings have roughly a 50 percent chance of carrying the same variant, and your children inherited one of your two copies. A genetic counselor can help if you are weighing what to share or if a variant comes back with uncertain meaning.